PTAB challenges

Proceedings overview

One AIA trial proceeding is on file for US patent 12016580. This proceeding is currently active with a "Trial Instituted" status, meaning a trial has been ordered but no final decision on patentability has been issued. This indicates that the patent's claims are currently being challenged, and their patentability remains undetermined by the PTAB.

IPR2025-01264 — Imperative Care, Inc. v. Inari Medical Inc.

• Type: Inter Partes Review
• Filed: 2025-07-08
• Status: Trial Instituted — A trial has been ordered by the Patent Trial and Appeal Board (PTAB), and the proceeding is currently ongoing.
• Judge panel: The specific panel of Administrative Patent Judges (APJs) assigned to conduct the trial for IPR2025-01264 is not publicly available in the provided search results. Institution decisions effective October 20, 2025, are made personally by USPTO Director John Squires in consultation with at least three PTAB judges, and routine decisions are issued without detailed explanation.
• Petition grounds: The specific claims challenged and the prior art references or statutory bases (§ 102 / § 103 / § 112) are not explicitly detailed in the public search results. Generally, IPRs challenge claims under 35 U.S.C. §§ 102 and/or 103.
• Institution decision: Instituted on 2025-12-11. Director Squires's decisions issued around this time began listing petitions that had overcome discretionary denial and were being considered on the merits, indicating institution. The reasoning for institution is not publicly detailed, as routine institution decisions under Director Squires's policy are issued as summary notices without written explanations.
• Final Written Decision (if issued): Not yet issued. The Final Written Decision is typically due one year from the institution date.
• Settlement / termination: No settlement or termination has been publicly reported for this proceeding as of 2026-05-19.
• Appeal: Not applicable, as no Final Written Decision has been issued yet.
• Defensive value: This proceeding indicates that the patentability of US12016580 is currently under review at the PTAB. While no claims have been invalidated, the active trial status means there is an ongoing challenge to the patent's validity. If a Final Written Decision ultimately cancels claims, those claims would be significantly weakened for any assertion.

Strategic summary

Currently, all claims of US12016580 are still considered active and untested by a Final Written Decision in IPR2025-01264. No claims have been CANCELED or SUSTAINED by the PTAB. The patent is actively undergoing an Inter Partes Review, with the trial having been instituted on 2025-12-11.

Regarding the estoppel landscape, if IPR2025-01264 proceeds to a Final Written Decision, the petitioner (Imperative Care, Inc.) and its privies would be estopped under 35 U.S.C. § 315(e)(2) from asserting in future civil actions or ITC proceedings any ground that was raised or reasonably could have been raised during the IPR with respect to the instituted claims. Since the specific claims challenged and prior art grounds are not publicly available, it is not possible to detail the precise scope of potential estoppel at this time.

There are no apparent pattern signals such as multiple IPRs filed by the same petitioner on this specific patent, nor any noted appeals by the patent owner yet, as no Final Written Decision has been rendered.

Recommended next steps

The IPR2025-01264 proceeding is active and currently in the trial phase. Given the institution date of 2025-12-11, the Final Written Decision for this IPR is statutorily due approximately one year from that date, which would be 2026-12-11. A defendant facing assertion of this patent should closely monitor this IPR for the issuance of the Final Written Decision, as it will determine the patentability of the challenged claims. The outcome of this proceeding will significantly impact the strength of US12016580.